Analyst Ratings For Radius Health (NASDAQ:RDUS)
Today, Morgan Stanley initiated coverage on Radius Health (NASDAQ:RDUS) with a Overweight with a price target of $57.00.
Some recent analyst ratings include
- 1/29/2018-Morgan Stanley initiated coverage with a Overweight rating.
- 1/22/2018-Citigroup Reiterated Rating of Hold.
- 1/18/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 10/6/2017-Goldman Sachs Group Reiterated Rating of Neutral .
- 9/29/2017-Maxim Group Reiterated Rating of Positive.
- On 11/14/2017 Growth N V Biotech, Major Shareholder, bought 50,000 with an average share price of $26.25 per share and the total transaction amounting to $1,312,500.00.
- On 11/10/2017 Brent Hatzis-Schoch, VP, bought 1,778 with an average share price of $28.09 per share and the total transaction amounting to $49,944.02.
- On 11/7/2017 Jesper Hoiland, Insider, bought 6,800 with an average share price of $29.04 per share and the total transaction amounting to $197,472.00.
- On 11/3/2017 Growth N V Biotech, Major Shareholder, bought 50,000 with an average share price of $29.15 per share and the total transaction amounting to $1,457,500.00.
- On 10/25/2017 Growth N V Biotech, Major Shareholder, bought 50,000 with an average share price of $32.85 per share and the total transaction amounting to $1,642,500.00.
- On 9/15/2017 Jesper Hoiland, Insider, bought 6,100 with an average share price of $32.72 per share and the total transaction amounting to $199,592.00.
- On 9/14/2017 Growth N V Biotech, Major Shareholder, bought 150,000 with an average share price of $33.45 per share and the total transaction amounting to $5,017,500.00.
Recent Trading Activity for Radius Health (NASDAQ:RDUS)
Shares of Radius Health closed the previous trading session at 39.98 up +1.24 3.20% with 40.275001525878906 shares trading hands.